MiMedx
Processor of donated placental tissue into allografts for wound care and surgical use.
Something off on this page? Send us feedback.
Profile
Turns donated placental and umbilical tissue into allografts for wound care and surgical use, marketed under brands such as EpiFix and AmnioFix and processed through proprietary PURION technology. Sales are concentrated in the United States and priced largely against Medicare fee schedules, with Japan the lead international market.
Processes donated placental membrane, umbilical cord, and placental-disc tissue into allografts for wound and surgical care, sold under brands including EpiFix, AmnioFix, EpiCord, and the newer Heliogen xenograft line, all built on proprietary PURION tissue processing.
A 2018 accounting scandal triggered a Nasdaq delisting and the eventual criminal conviction of the founding CEO; a rebuilt leadership team restored internal controls and returned to Nasdaq trading in 2020. Newer surgical-line launches now sit alongside the original wound-care franchise.
Domestic sales make up substantially all of the top line, with Japan established as the lead international market after EpiFix became the first amniotic wound-care tissue product approved there. Products are regulated by the FDA as human tissue allografts, exempt from premarket clinical trials but priced largely off Medicare fee schedules.
Company facts
Key statistics
Year to date −30.7% · Average volume (30d) 1.3M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 27, 2026 | Craig-Hallum | Reiterate | Buy | $8 | |
| Aug 17, 2026 | Raymond James | Target | $8 | ||
| Aug 17, 2026 | Seaport Global | Downgrade | Neutral | ||
| Jul 30, 2026 | Lake Street | Reiterate | Buy | $12 | $7 |
| Feb 23, 2026 | UBS | Target | $10 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026Q2 FY26 | −$0.05 | −$0.05 | −1.0% | $63.5M | $64.4M | +1.4% | +0.95% |
| Apr 29, 2026Q1 FY26 | −$0.07 | −$0.05 | +28.6% | $65.8M | $59.0M | −10.3% | +8.74% |
| Feb 25, 2026Q4 FY25 | $0.09 | $0.14 | +55.6% | $106.8M | $118.1M | +10.6% | −6.44% |
| Oct 29, 2025Q3 FY25 | $0.07 | $0.15 | +114.3% | $106.9M | $113.7M | +6.4% | +2.92% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $88.2M | $98.6M | $113.7M | $118.1M | $59.0M | $64.4M | |
| Gross profit | $71.6M | $79.9M | $95.0M | $99.0M | $41.6M | $44.4M | |
| Operating income | $8.3M | $12.4M | $22.2M | $21.1M | −$16.0M | −$18.5M | |
| Net income | $7.0M | $9.6M | $16.7M | $15.2M | −$10.9M | −$14.8M | |
| Diluted EPS | $0.05 | $0.06 | $0.11 | $0.10 | −$0.07 | −$0.10 | |
| Gross margin | 81.2% | 81.1% | 83.5% | 83.9% | 70.6% | 69.0% | |
| Operating margin | 9.4% | 12.5% | 19.5% | 17.8% | -27.2% | -28.7% |
Fiscal years (4-quarter sums)FY21 $258.6M · FY22 $267.8M · FY23 $321.5M · FY24 $348.9M · FY25 $418.6M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $135.8M · Total debt $1.5M · Total assets $281.0M · Shareholders' equity $216.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 145.76M · Float 115.44M · 79.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Essex Woodlands Management, Inc. | 28.20M | 19.34% | 13F | Aug 4, 2026 |
| BlackRock, Inc. | 12.15M | 8.34% | 13F | Aug 7, 2026 |
| Trigran Investments, Inc. | 7.17M | 4.92% | 13F | Aug 12, 2026 |
| State Street Corp | 5.58M | 3.83% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 5.19M | 3.56% | 13F | Aug 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Nov 6, 2025 | Kimberly Maersk-Moller | officer: Chief Commercial Officer | −58,300 | $7.42 |
Peers
- Organogenesis
Head-to-head in placental allografts and bioengineered skin substitutes
- Integra LifeSciences
Amniotic allografts, bovine xenografts, and surgical matrices overlap broadly
- Smith & Nephew (ADR)
GRAFIX/STRAVIX placental allografts plus a broad wound-care portfolio
- Vericel
Cultured epidermal autografts and eschar removal overlap in severe burn care
- Solventum
Negative-pressure therapy and dressings vie for the same wound-care budgets
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| MiMedx | $4.50 | +0.22% | $655.9M | 112.5 | 91.3 | 1.8 | −34.7% |
| Organogenesis | $1.74 | +0.29% | $223.9M | — | — | 0.5 | −56.7% |
| Integra LifeSciences | $16.89 | 0.00% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| Smith & Nephew (ADR) | $28.72 | −0.93% | $12.17B | 19.2 | — | 1.9 | +3.7% |
| Vericel | $40.95 | 0.00% | $2.10B | 87.5 | 61.6 | 6.8 | +22.5% |
| Solventum | $90.50 | −0.68% | $15.78B | 11.1 | 13.5 | 1.9 | +2.2% |
| Median | 19.2 | 13.5 | 1.9 | +2.2% |